TRCT
ADMS

Tower Research Capital (TRC)’s Adamas Pharmaceuticals ADMS Stock Holding History

Tower Research Capital (TRC)’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7,520
Closed -$40K – 6541
2021
Q2 		$40K Sell
7,520
-3,660
-33% -$18.9K ﹤0.01% 3227
2021
Q1 		$54K Buy
11,180
+8,154
+269% +$42.6K ﹤0.01% 3065
2020
Q4 		$13K Sell
3,026
-4,100
-58% -$17.5K ﹤0.01% 4181
2020
Q3 		$29K Buy
7,126
+6,299
+762% +$24.4K ﹤0.01% 3742
2020
Q2 		$2K Sell
827
-3,877
-82% -$11.4K ﹤0.01% 4563
2020
Q1 		$14K Buy
+4,704
New +$21.1K ﹤0.01% 1899
2019
Q4 		– Sell
-1,007
Closed -$5K – 4717
2019
Q3 		$5K Buy
+1,007
New +$6.22K ﹤0.01% 3367
2019
Q2 		– Sell
-2,093
Closed -$15K – 4578
2019
Q1 		$15K Buy
2,093
+1,337
+177% +$12K ﹤0.01% 2459
2018
Q4 		$6K Sell
756
-7,343
-91% -$95.5K ﹤0.01% 2847
2018
Q3 		$162K Buy
+8,099
New +$190K 0.01% 1092
2018
Q2 		– Sell
-2,241
Closed -$54K – 4267
2018
Q1 		$54K Buy
+2,241
New +$70.7K ﹤0.01% 1640
2017
Q4 		– Sell
-1,483
Closed -$31K – 4244
2017
Q3 		$31K Sell
1,483
-4,750
-76% -$87.1K ﹤0.01% 2423
2017
Q2 		$109K Buy
+6,233
New +$103K 0.01% 468
2017
Q1 		– Sell
-1,061
Closed -$18K – 4208
2016
Q4 		$18K Buy
+1,061
New +$16.4K ﹤0.01% 2257
2016
Q3 		– Sell
-100
Closed -$2K – 4770
2016
Q2 		$2K Sell
100
-5,077
-98% -$83.7K ﹤0.01% 4013
2016
Q1 		$75K Buy
+5,177
New +$87.2K 0.01% 588
2015
Q4 		– Sell
-2,838
Closed -$48K – 5278
2015
Q3 		$48K Buy
+2,838
New +$64.6K ﹤0.01% 1055
2015
Q2 		– Sell
-730
Closed -$13K – 5255
2015
Q1 		$13K Sell
730
-1,253
-63% -$21.5K ﹤0.01% 2593
2014
Q4 		$34K Buy
+1,983
New +$30.1K ﹤0.01% 1262
2014
Q3 		– Sell
-2,969
Closed -$54K – 5052
2014
Q2 		$54K Buy
+2,969
New +$53.2K 0.01% 1253

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CCPM
Cooper Creek Partners Management New York $2.92B AUM 30.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tower Research Capital (TRC)'s ADMS Position: Q3 2021 in Review

Tower Research Capital (TRC) sold out of Adamas Pharmaceuticals (ADMS) in Q3 2021, closing a stake of 7,520 shares — an estimated $40K sold.

Tower Research Capital (TRC) first reported a position in ADMS in Q2 2014 and held it in 20 quarters. The position peaked at $162K in Q3 2018. 63 funds tracked by Wall St. Rank hold ADMS as of Q3 2021.

  • Tower Research Capital (TRC) reported no remaining Adamas Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 7,520 Adamas Pharmaceuticals shares in Q3 2021, an estimated $40K.
  • Tower Research Capital (TRC) first reported a position in Adamas Pharmaceuticals in Q2 2014 and held it in 20 quarters.
  • Tower Research Capital (TRC)'s Adamas Pharmaceuticals position peaked at $162K in Q3 2018.
  • 63 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2021.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2021, filed 15 Nov 2021.